ALK and non-small cell lung carcinoma: The PROFILE 1013 study demonstrated that 2-year progression free survival of 63% in relapsed/refractory ALK+ patients with crizotinib monotherapy.[12] On the contrary, the long-term usage of ALK inhibitors in NSCLC patients showed resistance to the drugs.[23,24] Another question is whether we should use ALK inhibitors as a first-line therapy or not.